Notes in Systemic therapy

To Subscribe, use this Key

Status	Last Update	Fields
Published	02/18/2024	ClinOnc \| Systemic therapy \| Combination with RT \| Immunotherapy and radiotherapy
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimicrotubule agents \| Taxanes
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Platinum agents
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimetabolites \| Antifolates
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimetabolites \| Purine analogs
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimetabolites \| 5-Fluoropyrimidines
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimetabolites \| Gemcitibine and Cytarabine
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimetabolites \| Fludarabine
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 1 \| General principles
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 3 \| Top2 \| Anthracyclines
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 2 \| Top1 \| Campothecins (Irinotecan)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 4 \| Top2 \| Mitoxanthrone
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 5 \| Top2 \| Dactinomycin
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 6 \| Top2 \| Etoposide
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Topoisomerase inhibitors \| 7 \| Summary table
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Antimicrotubule agents \| Vinca alkaloids
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Bleomycin
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| SHH pathway inhibitors \| Vismodegib
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Procarbazine
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 1 \| General
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 2 \| Nitrogen mustards (incl. cyclophosphamide)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 3 \| Triazenes (incl. temozolomide)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 5 \| Nitrosureas (incl. carmustine)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 4 \| Alkyl sulfonates (Busulfan)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cytotoxic chemotherapy \| Alkylating agents \| 6 \| Thio TEPA
Published	02/18/2024	Clinonc \| Systemic therapy \| Histone deacetylase inhibitors and demethylating agents (Azacitidine and vorinostat)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Proteasome inhibitors (incl. Bortezomib)
Published	02/18/2024	ClinOnc \| Systemic therapy \| Combination with RT \| Chemoradiotherapy principles
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| PARP inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| Her2 \| ADO-Trastuzumab Emtansine (T-DM1) (Kadcyla)
Published	02/18/2024	ClinOnc \| Systemic therapy \| mTOR inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Lenalidomide
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| Her2 \| Trastuzumab, Pertuzumab
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| Breast \| SERMs
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| Breast \| Aromatase inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| GnRH analogs / antagonists \| SE detail
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| GnRH analogs / antagonists
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| Antiandrogens
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| Novel antiandrogens
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted agents \| BRAF / MEK inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Kinase inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| EGFR inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted agents \| Anti-angiogenic
Published	02/18/2024	ClinOnc \| Systemic therapy \| Cell cycle inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Immunotherapy \| Immune checkpoint inhibitors
Published	02/18/2024	ClinOnc \| Systemic therapy \| Immunotherapy \| Intravesical BCG
Published	02/18/2024	ClinOnc \| Systemic therapy \| Bisphosphanates
Published	02/18/2024	ClinOnc \| Systemic therapy \| Endocrine \| Breast \| SE management
Published	02/18/2024	ClinOnc \| Systemic therapy \| Targeted therapy \| Her2 \| General
Status	Last Update	Fields